Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA [Seeking Alpha]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Seeking Alpha
The company reported a loss from operations of $194 million in 2023, with $378.1 million in cash at the end of the year. Geron stock has risen by 12% since December, but faces potential risks from an upcoming FDA Advisory Committee meeting and competition from Bristol-Myers Squibb's Reblozyl. If approved, and despite the competition, GERN stock could recapture former highs of $3.5 per share, making this is a potentially exciting, albeit risky, "buy" opportunity. Investment Overview I last updated on Geron Corporation NASDAQ: GERN ), the Foster City, California-based biotech primarily focused on securing commercial approval in the U.S. for its lead candidate, imetelstat, in the indication of transfusion-dependent anemia in adult patients, with low-to-intermediate-1 risk myelodysplastic syndromes ("MDS"), in a note for Seeking Alpha back in early December last year. I gave the company and its stock a "Buy" rating, based on my belief that the FDA is likely to approve Imetelsta
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire
- Baird downgrades Geron to neutral, cites valuation concerns [Seeking Alpha]Seeking Alpha
- Geron Co. (NASDAQ: GERN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $4.50 price target on the stock.MarketBeat
- Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
GERN
Earnings
- 5/2/24 - Beat
GERN
Sec Filings
- 5/2/24 - Form 8-K
- 3/27/24 - Form ARS
- 3/27/24 - Form DEFA14A
- GERN's page on the SEC website